FDA approves Tukysa with Herceptin and Perjeta as maintenance therapy for metastatic HER2-positive breast cancer. Here is who qualifies and the tradeoffs.
Tukysa Wins FDA Nod for First-Line HER2-Positive Breast Cancer Maintenance After Trial Showed 8.6-Month Longer Median Disease Control
by | Oct 8, 2026 | Uncategorized | 0 comments
Recent Comments